OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Help
Advanced
Search
9
Results
Show all
Save search
Copy query
Show results for
Unknown
(9)
Publication Date
Release Date
2025
(3)
2020
(3)
2024
(2)
2019
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course.
Not available
S-EPMC6912490
|
biostudies-literature
Cite
Relationship Between Severity of Ischemia and Coronary Artery Disease for Different Stress Test Modalities in the ISCHEMIA Trial.
Not available
S-EPMC11658795
|
biostudies-literature
Cite
Management of Coronary Disease in Patients with Advanced Kidney Disease.
Not available
S-EPMC7274537
|
biostudies-literature
Cite
Health Status after Invasive or Conservative Care in Coronary and Advanced Kidney Disease.
Not available
S-EPMC7255621
|
biostudies-literature
Cite
Extended pharmacological thromboprophylaxis and clinically relevant venous thromboembolism after major abdominal and pelvic surgery: international, prospective, propensity score-weighted cohort study.
Not available
S-EPMC11894929
|
biostudies-literature
Cite
Factors Associated With Coronary Angiography Performed Within 6 Months of Randomization to the Conservative Strategy in the ISCHEMIA Trial.
Not available
S-EPMC11187765
|
biostudies-literature
Cite
Initial Invasive or Conservative Strategy for Stable Coronary Disease.
Not available
S-EPMC7263833
|
biostudies-literature
Cite
Health Status Outcomes With Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting in ISCHEMIA.
Not available
S-EPMC12492304
|
biostudies-literature
Cite
Evaluating the Appropriate Use Criteria for Coronary Revascularization in Stable Ischemic Heart Disease Using Randomized Data From the ISCHEMIA Trial.
Not available
S-EPMC11919559
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets